Long-term damage to the ENT system in Wegener's granulomatosis

European Archives of Oto-Rhino-Laryngology

Volumn 268, Issue 5, 2011, Pages 733-739

  Martinez Del Pero, Marcos ^a   Walsh, Michael ^b   Luqmani, Raashid ^c   Flossmann, Oliver ^d   Mukhtyar, Chetan ^e   Jani, Piyush ^a   Rasmussen, Niels ^f   Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f Rigshospitalet   (Denmark)

Author keywords

ANCA associated vasculitis; Damage; Ear; Nose and throat; Otolaryngology; Wegener's granulomatosis

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PR 39;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG PULSE THERAPY; EAR NOSE THROAT DISEASE; ENT EXAMINATION; FEMALE; FOLLOW UP; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RISK FACTOR; VASCULITIS DAMAGE INDEX; WEGENER GRANULOMATOSIS;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 79956126359     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-010-1421-x     Document Type: Article

References (26)

1. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B et al (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43:1021-1032 (Pubitemid 30368179)
2. Jayne D (2005) How to induce remission in primary systemic vasculitis. Best Pract Res 19:293-305
3. Wegener F (1990) Wegener's granulomatosis. Thoughts and observations of a pathologist. Eur Arch Otorhinolaryngol 247:133-142
4. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-192
5. Stone JH (2003) Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 48:2299-2309
6. Merkel PA, Herlyn K, Mahr AD, Neogi T, Seo P, Walsh M et al (2009) Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. J Rheumatol 36:2362-2368
7. Herlyn K, Seo P, Hellmich B, Reimer J, Merkel PA (2009) Patient-reported outcome assessment in primary systemic vasculitis with a new instrument provides a unique perspective (abstract). APMIS 117(Suppl 127):149
8. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371-380 (Pubitemid 27114101)
9. Seo P, Luqmani RA, Flossmann O, Hellmich B, Herlyn K, Hoffman GS et al (2007) The future of damage assessment in vasculitis. J Rheumatol 34:1357-1371 (Pubitemid 46898123)
10. Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P et al (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66:283-292 (Pubitemid 46579626)
11. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L et al (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66:605-617 (Pubitemid 46707128)
12. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670-680
13. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J et al (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349:36-44 (Pubitemid 36765101)
14. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180-2188 (Pubitemid 47041083)
15. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:2461-2469 (Pubitemid 41117433)
16. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:1101-1107 (Pubitemid 20273294)
17. Koldingsnes W, Nossent H (2002) Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 41:572-581 (Pubitemid 34567189)
18. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488-498
19. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM et al (1992) Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a subcommittee of the British Thoracic Society Research Committee. Q J Med 83:427-438
20. Exley AR, Carruthers DM, Luqmani RA, Kitas GD, Gordon C, Janssen BA et al (1997) Damage occurs early in systemic vasculitis and is an index of outcome. Q J Med 90:391-399 (Pubitemid 27254195)
21. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R et al (2005) Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52:2168-2178 (Pubitemid 40994340)
22. Lee RW, D'Cruz DP (2008) Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs 68:747-770 (Pubitemid 351550529)
23. Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262-268 (Pubitemid 40129256)
24. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D (2009) B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 34:328-335
25. Cannady SB, Batra PS, Koening C, Lorenz RR, Citardi MJ, Langford C et al (2009) Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope 119:757-761
26. Bakthavachalam S, Driver MS, Cox C, Spiegel JH, Grundfast KM, Merkel PA (2004) Hearing loss in Wegener's granulomatosis. Otol Neurotol 25:833-837 (Pubitemid 39232111)